Clinical Trial Update: 18F-mFBG Cardiac Uptake With Lewy Body Dementia [Phase 2]

View source ↗

Summary

A Phase 2 study is evaluating cardiac uptake of the radiopharmaceutical 18F-mFBG in patients with Parkinson disease and Lewy body dementia and is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lewy Body Dementia
• Parkinson Disease

Drugs mentioned

• [18F]-MFBG (18F-MFBG)

Snippet

Sponsor: Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | Conditions: Parkinson Disease (PD), Lewy Body Dementia (LBD) | Phase 2 | Status: RECRUITING